Cargando…
MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS
Cognitive impairment is emerging as an important therapeutic target in patients with psychiatric illnesses, including major depressive disorder (MDD). The objective of this general overview is to briefly review the evidence for cognitive impairment in MDD and to summarize a representative sample of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407945/ https://www.ncbi.nlm.nih.gov/pubmed/25421437 http://dx.doi.org/10.1002/da.22297 |
_version_ | 1782367990784720896 |
---|---|
author | Russo, Manuela Mahon, Katie Burdick, Katherine E |
author_facet | Russo, Manuela Mahon, Katie Burdick, Katherine E |
author_sort | Russo, Manuela |
collection | PubMed |
description | Cognitive impairment is emerging as an important therapeutic target in patients with psychiatric illnesses, including major depressive disorder (MDD). The objective of this general overview is to briefly review the evidence for cognitive impairment in MDD and to summarize a representative sample of cognitive assessment tools currently available to assess cognitive function in depressed patients. Study results in MDD patients with cognitive dysfunction are somewhat inconsistent, likely due to the heterogeneity of the disorder as well as the use of diverse assessment tools. Measuring cognitive changes in this population is challenging. Cognitive symptoms are typically less severe than in patients with schizophrenia and bipolar disorder, requiring greater sensitivity than afforded by existing tools. Preliminary evidence suggests antidepressant treatments may improve cognitive functioning as a direct result of ameliorating depressive symptoms; however, any procognitive effects have not been elucidated. To evaluate antidepressant efficacy in MDD patients with cognitive dysfunction, a standardized cognitive battery for use in clinical trials is essential. |
format | Online Article Text |
id | pubmed-4407945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44079452015-04-27 MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS Russo, Manuela Mahon, Katie Burdick, Katherine E Depress Anxiety Review Cognitive impairment is emerging as an important therapeutic target in patients with psychiatric illnesses, including major depressive disorder (MDD). The objective of this general overview is to briefly review the evidence for cognitive impairment in MDD and to summarize a representative sample of cognitive assessment tools currently available to assess cognitive function in depressed patients. Study results in MDD patients with cognitive dysfunction are somewhat inconsistent, likely due to the heterogeneity of the disorder as well as the use of diverse assessment tools. Measuring cognitive changes in this population is challenging. Cognitive symptoms are typically less severe than in patients with schizophrenia and bipolar disorder, requiring greater sensitivity than afforded by existing tools. Preliminary evidence suggests antidepressant treatments may improve cognitive functioning as a direct result of ameliorating depressive symptoms; however, any procognitive effects have not been elucidated. To evaluate antidepressant efficacy in MDD patients with cognitive dysfunction, a standardized cognitive battery for use in clinical trials is essential. Blackwell Publishing Ltd 2015-04 2014-11-24 /pmc/articles/PMC4407945/ /pubmed/25421437 http://dx.doi.org/10.1002/da.22297 Text en © 2014 The Authors. Depression and Anxiety published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Russo, Manuela Mahon, Katie Burdick, Katherine E MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS |
title | MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS |
title_full | MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS |
title_fullStr | MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS |
title_full_unstemmed | MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS |
title_short | MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS |
title_sort | measuring cognitive function in mdd: emerging assessment tools |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407945/ https://www.ncbi.nlm.nih.gov/pubmed/25421437 http://dx.doi.org/10.1002/da.22297 |
work_keys_str_mv | AT russomanuela measuringcognitivefunctioninmddemergingassessmenttools AT mahonkatie measuringcognitivefunctioninmddemergingassessmenttools AT burdickkatherinee measuringcognitivefunctioninmddemergingassessmenttools |